Ask AI
ProCE Banner Activity

Exploring TROP2 and TIGIT Therapies in Lung Cancer: Lessons From Recent Trials and Looking Forward to New Horizons

Clinical Thought

Read this commentary with the latest expert opinions on new and emerging evidence for TROP2-targeted antibody–drug conjugates and TIGIT-targeted monoclonal and bispecific antibodies for advanced NSCLC and ES-SCLC and how they are or may change the treatment paradigms.

Released: December 23, 2025

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This educational activity is intended for oncologists and other healthcare professionals who care for patients with lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate recently presented clinical research findings and expert guidance to support treatment selection and sequencing of investigational agents targeting TROP-2 and TIGIT in patients with lung cancer

  • Identify appropriate patients for enrollment in clinical trials of TROP-2–directed ADCs and anti-TIGIT/anti–PD-L1 combinations in lung cancer

Disclosure

Primary Author

Benjamin Levy, MD, FASCO: consultant/advisor/speaker: AstraZeneca, DSI, Janssen, Merck, Pfizer.

Alex Spira, MD, PhD, FASCO: consultant/advisor/speaker: Boehringer Ingelheim, Johnson & Johnson.